Passage BIO Q3 2026 Results: Net Loss of $4.72M, Loss Narrows
Passage Bio reported a net loss of $20.1 million for the nine months ended September 30, 2026, as it began winding down its gene therapy programs and entered into a merger agreement. Total assets decreased significantly from $62.3 million at year-end 2025 to $20.8 million, primarily due to the reduction in cash and the termination of lease assets.
- Key figure
- Net loss $4.72M